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Abstract
Although misfolded and aggregated a-synuclein (a-syn) is recog-
nized in the disease progression of synucleinopathies, its role in
the impairment of cortical circuitries and synaptic plasticity
remains incompletely understood. We investigated how a-synu-
clein accumulation affects synaptic plasticity in the mouse
somatosensory cortex using two distinct approaches. Long-term
in vivo imaging of apical dendrites was performed in mice overex-
pressing wild-type human a-synuclein. Additionally, intracranial
injection of preformed a-synuclein fibrils was performed to induce
cortical a-syn pathology. We find that a-synuclein overexpressing
mice show decreased spine density and abnormalities in spine
dynamics in an age-dependent manner. We also provide evidence
for the detrimental effects of seeded a-synuclein aggregates on
dendritic architecture. We observed spine loss as well as
dystrophic deformation of dendritic shafts in layer V pyramidal
neurons. Our results provide a link to the pathophysiology underly-
ing dementia associated with synucleinopathies and may enable
the evaluation of potential drug candidates on dendritic spine
pathology in vivo.
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Introduction
The mammalian brain contains a complex network of billions of
neurons communicating through different types of synapses that
can be severely and irreversibly disturbed by neurodegeneration. In
synucleinopathies like Parkinson’s disease (PD) or dementia with
Lewy bodies (DLB), progressive neurodegeneration is linked to
misfolding and intracellular aggregation of the synaptic protein
a-synuclein (a-syn; Clayton & George, 1999; Lu¨cking & Brice, 2000)
and leads to motor as well as cognitive deficits and ultimately to
dementia (Spillantini et al, 1997; Burn, 2004; Aarsland et al, 2008).
Familial cases of PD or DLB can be caused by mutations in the
a-syn gene (Polymeropoulos et al, 1997; Kru¨ger et al, 1998; Zarranz
et al, 2004) or overexpression of a-syn (Simo´n-Sa´nchez et al, 2009)
and strengthen the association between protein load/aggregation
and the onset of disease. Although the filamentous, cytosolic a-syn
inclusions called Lewy bodies (Spillantini et al, 1998) are a prereq-
uisite for the histopathological diagnosis of PD and DLB, only an
imperfect correlation between the Lewy body load and severity of
cognitive impairment is known (Hughes et al, 1992; Parkkinen et al,
2005). Several studies rather support synaptic failure as the predom-
inant pathophysiological mechanism. Presynaptic neurotransmitter
release has been proven to be unbalanced in PD (Nikolaus et al,
2009). Moreover, presynaptic a-syn oligomers and micro-aggregates
are thought to be responsible for neurodegeneration as well as for
dendritic spine loss observed in postmortem DLB brains (Kramer &
Schulz-Schaeffer, 2007).
Over the past few years, an increasing body of evidence supports
the concept of the propagation of misfolded a-syn species from
neuron to neuron, where they are transported along axons and trig-
ger the conversion of endogenous a-syn into a pathologic form in
culture and in vivo (Luk et al, 2012a,b). Aspects of progressive
a-syn aggregation—namely the spread along synaptically connected
brain regions and the maturing of Lewy-like inclusions—can be
recapitulated in model systems by exogenous introduction of
in vitro-generated, preformed fibrils (PFFs) of a-syn, which under
certain conditions is even possible in non-transgenic animals (Luk
et al, 2012a,b; Masuda-Suzukake et al, 2013; Osterberg et al, 2015).
Dendritic spines are small protrusions from the dendritic shaft
which are highly regulated and have been shown to be altered in
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several neurological disorders including neurodegenerative diseases
(Fiala et al, 2002; Penzes et al, 2011; Murmu et al, 2013). Various
studies in the field of a-syn-related disorders have addressed the
impairment of dendritic spines in brain areas like the striatum
(McNeill et al, 1988; Day et al, 2006; Zaja-Milatovic et al, 2006;
Finkelstein et al, 2016), the hippocampus (Winner et al, 2012), the
olfactory bulb (Neuner et al, 2014), and naturally the substantia
nigra (Patt et al, 1991). However, chronic effects of cortical a-syn
have not been studied extensively, even though it is becoming more
and more evident that the cortical involvement in the pathophysiol-
ogy of PD and DLB cannot be neglected.
This study aims to extend the understanding of the structural
consequences of neocortical a-syn accumulation on dendritic spines
in a time-resolved manner. To address this question, we used
chronic two-photon in vivo imaging to monitor spine dynamics over
time, in young and aged transgenic mice overexpressing human
wild-type a-synuclein (PDGF-h-a-syn) (Masliah, 2000). Further-
more, we used PFFs as a tool to induce cortical a-syn accumulation
in mice expressing only the reporter transgene eGFP in order to
study the structural consequences of a-syn seeding on dendritic
architecture and spines.
Here, we report detrimental effects on dendrites and dendritic
spines due to a-syn overexpression as well as seeding. Accumula-
tion of a-syn in the neocortex triggers the loss of dendritic spines,
interferes with spine dynamics, and leads to dystrophic malforma-
tion of dendritic branches. Our combination of a transgenic and a
PFF-seeding mouse model provides new insights on the a-syn-
dependent mechanisms that lead to dendritic spine decay in the
cortex and therefore might create a better understanding of cogni-
tive decline in synucleinopathies.
Results
Overexpression of wild-type human a-synuclein leads to changes
in dendritic spine density and dynamics in aged mice
In vivo two-photon imaging was performed in three age groups of
mice (3, 6, and 12 months), which were chosen according to previ-
ously published data on the progression of a-syn accumulation and
its corresponding behavioral phenotype (Masliah, 2000; Rockenstein
et al, 2002; Amschl et al, 2013). We consider the 3-month-old
cohort as “presymptomatic”, whereas the 6- and 12-month-old
cohorts show a developing and fully fledged phenotype,
respectively.
Previous long-term in vivo imaging studies have shown that
spines are highly dynamic structural elements and can be classified
accordingly: Persistent spines are long lasting and stable for weeks
up to the entire life span, whereas transient spines are newly formed
and lost within days (Grutzendler et al, 2002; Trachtenberg et al,
2002; Holtmaat et al, 2005). In both h-a-syn transgenic and control
mice, dendritic images were analyzed for spine density and dynam-
ics. Newly appeared and disappeared spines relative to the previous
imaging session were marked as “gained” or “lost”, respectively.
Spines that were gained at a certain time point and persisted for
< 7 days were considered as being “transient” (Fig 1A).
Our image analysis in the 6- and 12-month-old cohorts revealed
that the number of spines per lm was significantly lowered in mice
overexpressing h-a-syn. The ANOVA genotype main factor was
significantly changed (6 M: F(1,7) = 27.11; P = 0.0012 and 12 M:
F(1,7) = 55.78; P = 0.0001), denoting that h-a-syn mice exhibit
considerably less (30%) dendritic spines on apical tuft dendrites
but show no increase or decrease in spine density over the imaging
time period relative to controls (Fig 1B).
Concerning spine dynamics, the fractions of both gained and lost
spines were found to be elevated; however, only the comparison of
the lost fractions reached statistical significance (6 M: F(1,7)= 5.85;
P = 0.0461 and 12 M: F(1,7) = 8.86; P = 0.0206). As newly gained
spines were disproportionally more often lost again, the fraction of
transient spines showed a significant increase in both 6- and 12-
month-old h-a-syn mice (6 M: F(1,7) = 7.19; P = 0.0315 and 12 M:
F(1,7) = 24.25; P = 0.0017; Fig 1C).
As a consequence of the change in spine dynamics, the daily
turnover ratios were found to be significantly elevated in h-a-syn
mice (6 M: F(1,7) = 5.65; P = 0.0491 and 12 M: F(1,7) = 6.93;
P = 0.0338; Fig 1D). In summary, we could show that spine
density is significantly reduced and does not further change over
the imaging interval of 35 days. Moreover, parameters of spine
dynamics were profoundly changed in mice overexpressing a-syn
compared to controls. The significant increase in transient spine
fraction both in 6 and 12 months of age indicates that compen-
satory mechanisms may take place. Since there are no significant
differences between 6 and 12 months of age, spine pathology does
not further progress after 6 months of age but has reached a stable
equilibrium.
Young adult a-synuclein overexpressing mice exhibit a different
dynamic phenotype than aged mice
In order to reveal when the spine loss starts leading to reduced spine
density in 6- and 12- month-old h-a-syn mice, we analyzed a
3-month-old cohort over 6 weeks. Different to the older cohort, we
observed a progressive decrease in spine density, with a significant
interaction between genotype and time in Bonferroni’s post hoc test
(F(5,30) = 15.18; P < 0.001). Compared to controls, spine density in
h-a-syn mice was reduced 12% on average at the first imaging time
point (age of mice: 3 months) and 30% at the last imaging time
point (age of mice: 4.5 months; Fig 2A).
Moreover, the dynamic fractions of spines show a somewhat
contradictory picture compared to the 6- and 12-month-old mice.
Our data revealed a significant impairment in the formation of new
spines in h-a-syn mice (F(1,6) = 8.71; P = 0.0256), while the fraction
of lost spines was unaffected, which accounts for the progressive
decrease in spine density. By implication, stable spines represent a
significantly larger fraction in these mice (F(1,6) = 8.71; P = 0.0256),
while the fraction of transient spines is not significantly different
from controls (Fig 2B). We also observed no significant change of
the daily turnover ratio (TOR) between the groups at 3 months of
age (Fig 2C).
Our results demonstrate that overexpression of human a-syn
leads to structural alterations of dendritic spines in the cerebral
cortex. The alterations develop already in young adults at the age
of 3–4.5 months, significantly before behavioral or motoric pheno-
types become apparent (Amschl et al, 2013), but reach a state of
dynamic equilibrium later and do not progress further until
12 months of age.
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Alterations in spine density and morphology in young adult and
aged PDGF-h-a-syn mice
The progressive decrease in spine density seen in young adult mice
could be monitored in vivo between 3 and 4.5 months of age.
Extrapolation of the data curve (Fig 2A) of a-syn overexpressing
animals to an earlier age would yield a time point at which no dif-
ference in synaptic spine densities between the groups is present. As
chronic in vivo imaging in younger mice is technically not possible
(bone growth in mice until 6–8 weeks of age, 4 weeks postsurgery
necessary for chronic window clearing/healing), we addressed this
question with a single time point ex vivo approach. Confocal
A
C D
B
Figure 1. a-Synuclein overexpression alters spine density and dynamics in vivo.
A Representative in vivo two-photon recordings of eGFP-labeled apical tuft dendrites in the somatosensory cortex in h-a-syn and control animals. Arrowheads mark
representative spines that were stable (white, present > 7 days), newly formed (green), or lost (magenta). Gained spines that do not stabilize (yellow/green, present
< 7 days) are defined as transient. Scale bar, 5 lm.
B Spine density is reduced in both 6- (**P = 0.0012) and 12-month-old (***P = 0.0001) h-a-syn animals.
C The fractions of both gained (P6 months = 0.0527; P12 months = 0.0678) and lost spines (*P6 months = 0.0461; *P12 months = 0.0206) are elevated in h-a-syn mice
compared to controls; the fraction of transient spines is significantly higher (*P6 months = 0.0315; **P12 months = 0.0017).
D Consequently, the daily turnover ratio (TOR) is significantly increased in both 6- and 12-month-old h-a-syn mice (*P6 months = 0.0491; *P12 months = 0.0338).
Data information: n = 5 (h-a-syn), n = 4 (control) animals, mean with s.e.m.; two-way ANOVA genotype main factor, *P < 0.05, **P < 0.01, ***P < 0.001.
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imaging of apical tuft dendrites (layer I) was performed in brain
slices of control as well as h-a-syn mice that were 2 and 4.5 months
old. Note that the higher resolution of confocal microscopy in brain
slices leads to an overall increased detection of spine density and a
better ability to judge spine morphology. Two remarkable dif-
ferences concerning the age and the genotype of the animal were
observed. Firstly, at 2 months of age, there was no difference in
spine density between control and transgenic animals, whereas at
4.5 months, spine density in h-a-syn mice showed a ~40% decrease
(t(6) = 5.770; P = 0.0012) relative to age-matched controls.
Secondly, there was a significant difference in the spine densities of
the h-a-syn mice (t(6) = 4.097; P = 0.0064; ~30% reduction at
4.5 months) depending on their age, whereas this had no impact on
the spine densities of control animals (Fig 2D).
In order to clarify whether the progressive spine loss in h-a-syn
mice is reflected by changes in spine morphology, we furthermore
analyzed spine shape for which three morphological subtypes have
been defined (Rochefort & Konnerth, 2012). Thin spines have an
elongated appearance, with a long neck and a small spine head.
Mushroom spines have the largest, round head, while stubby spines
are devoid of a neck and appear as round elevation from the
dendritic shaft. In addition, filopodia are very long and thin struc-
tures that lack a spine head and are considered the most dynamic of
dendritic structures, which appear and disappear rapidly and only
sometimes develop into one of the other spine types. In the morpho-
logical analysis of our confocal data, the absolute numbers
(Appendix Fig S1A) as well as the fractions of mushroom, stubby
and thin spines as well as filopodia, were comparable in 2-month-
old mice independent of the expression of human a-syn (Fig 2D).
In 4.5-month-old h-a-syn mice, the density of all morphological
spine types is decreased (Appendix Fig S1A); however, not all types
are lost to the same extent. The normalized fractions reveal a slight
increase in the fraction of stubby spines (t(6) = 2.579; P = 0.0418),
whereas thin spines clearly represent a smaller fraction compared
both to age-matched controls (t(6) = 3.346; P = 0.0155) and to
younger h-a-syn mice (t(6) = 4.443; P = 0.0044) (Fig 2D).
The confocal imaging data from aged mice confirmed the reduc-
tion in spine density of ~30% in both 7.5- and 13.5-month-old h-a-
syn brains. Compared to controls, the fractions of mushroom spines
were decreased, while the fractions of thin spines were increased
(Fig 2E and Appendix Fig S1B).
Taken together, our data confirmed our hypothesis that struc-
tural changes of dendritic spines develop within a certain time frame
in young a-syn overexpressing mice. This time frame was deter-
mined to be approximately between 2 and 4.5 months of age.
Before, the dendritic appearance in these mice is indistinguishable
from healthy controls. Later, a-syn overexpression causes changes
in dendritic spines toward an overall lower spine density and a shift
in spine morphology.
Intrastriatal injection of preformed a-synuclein fibrils triggers a
progressive spread of endogenous protein aggregation
a-syn pathology can be induced in wild-type mice by injecting
preformed fibrils (PFFs) (Luk et al, 2012a). Using this as a tool
to investigate whether seeded pathology of disease-associated
a-syn will lead to structural alterations in synapses, we injected
healthy 2-month-old GFP-M mice with PFFs prepared in vitro.
Prior to injection, the quality of the injection material was
controlled. The amyloid nature of PFFs was confirmed in a thio-
flavin T (ThT) assay, as ThT changes its fluorescent properties
upon binding to amyloid b-sheet structures (Fig 3A). Differential
centrifugation through a sucrose gradient confirmed the strongly
increased sedimentation coefficient and thus the increased molec-
ular density of PFFs compared to a-syn monomers (Fig 3B).
Finally, an electron micrograph visualized the fibrillary structure
of PFFs (Fig 3C).
Sonicated PFFs were stereotactically injected into the striatum
(Fig 3D), an area which contains extensive efferent and afferent
projections to other brain regions and is affected in PD (Shepherd,
2013). As cortical neurons are the targets of interest in this study,
the time-course and extent of a-syn pathology progression into dif-
ferent layers of the neocortex was monitored at different days
postinjection (dpi). The phosphorylation of a-syn at S129 (pS129) is
widely considered as a pathologic posttranslational modification
(Tenreiro et al, 2014; Oueslati, 2016) and was used in this study to
identify pathologic inclusions.
Striatal injection of PFFs resulted in intraneuronal aggregation of
phosphorylated a-syn (pS129-immunopositive) in the neocortex, at
first confined to layer IV and V neurons (30–150 dpi), developing
later to spread over all cortical layers (9 months postinjection;
Fig 3E). pS129-a-syn inclusions appeared as cytoplasmic fibrillary
forms (Fig 3F), which could also be stained by anti-ubiquitin
(Fig 3G) and thioflavin S (Fig 3H and I), thereby presenting Lewy-
body-like traits. Inclusions were also observed in the contralateral
cortex relative to the injection site and the amygdala (Appendix Fig
S2B). Due to a reported cross-reactivity between the pS129 antibody
and phosphorylated neurofilament subunit L (NFL; Sacino et al,
2014b), we confirmed the presence of phosphorylated a-synuclein
inclusions with a costaining for NFL (Appendix Fig S2B and C). The
◀ Figure 2. a-Synuclein overexpression alters spine density, dynamics, and morphology differently depending on age.A In young, 3-month-old h-a-syn mice, progressive decrease in spine density is observed in vivo.
B The loss of spines in young h-a-syn animals is driven by a reduced fraction of newly gained spines, while the fraction of lost spines remains unchanged and the
fraction of stable spines is increased (*Pgained/stable = 0.0256).
C The daily turnover of spines shows no significant difference between groups (P = 0.4062).
D Ex vivo confocal data in young mice confirm synapse loss in h-a-syn mice between 2 and 4.5 months of age (**Psyn 2/4.5 months = 0.0064; **Pctrl/syn 4.5 months = 0.0012)
and show a shift in spine morphology toward relatively more stubby (*pstubby = 0.0418) and less thin spines (**Ph-a-syn 2/4.5 months = 0.0044; *Pctrl/syn 4.5 months =
0.0155).
E Ex vivo confocal data in aged h-a-syn mice show a decrease in total spine density (***P7.5 months = 0.0005; **P13.5 months = 0.0039) as well as in the fraction of
mushroom spines (***P7.5 months = 0.0004; *P13.5 months = 0.0298), whereas the fraction of thin spines is increased (**P7.5 months = 0.0097; *P13.5 months = 0.0155).
Data information: (A–C) n = 4 animals per group; (D, E) n = 3–4 animals per group as illustrated; mean with s.e.m.; Bonferroni’s post hoc test (A): #P < 0.05, ##P < 0.01;
two-way ANOVA genotype main factor (B, C): *P < 0.05, **P < 0.01, ***P < 0.001; Student’s t-test (D, E): *P < 0.05, **P < 0.01, ***P < 0.001.
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presence of pS129-a-syn inclusions across different brain regions is
shown in Appendix Fig S2D.
Control brains injected with PBS did not show comparable
immunopositive inclusions (Fig 3E). Importantly, also monomeric
a-syn injected into GFP-M mice as well as PFFs injected into a-syn
knock-out mice (SNCA KO) failed to induce the phenotype as
observed after injection of PFFs (Appendix Fig S2E).
In order to further examine whether the effect can be attributed
to templated conversion of endogenous mouse a-syn into misfolded
and aggregated species rather than just the uptake of PFFs by cells,
control injections of fluorescently labeled PFFs into the striatum
were performed. Twenty-four hours after the injection, the injection
material was prominently detectable in the striatum, corpus callo-
sum, and the injection canal (Appendix Fig S3B and C). At 6 dpi,
however, the fluorescent material was removed from the injection
site (Appendix Fig S3D) and later showed very little colocalization
with developing pS129-a-syn-positive aggregates at 30 dpi
(Appendix Fig S3E and F). We therefore conclude that the spreading
of intracellular a-syn aggregation in our model is dependent on the
introduction of fibrillary a-syn as a molecular template on top of
endogenous a-syn expression and not simply due to a cellular
uptake of injected PFFs.
Considering inflammation as a contributor in neurodegenerative
diseases (Perry et al, 2010) and synaptic plasticity (Morris et al,
2013) and as PFF-induced a-syn accumulations have been associ-
ated with microglia (Sacino et al, 2014a), we assessed the presence
and activation of microglia in the neocortex with two markers. Anti-
Iba-1 marks all microglial cells including their processes, CD68 is a
marker associated with active phagocytosis. We find that at the time
point of spine analysis (5 months postinjection), the cortical area
covered by microglia shows a tendency toward higher coverage,
especially in layer IV (Appendix Fig S4A and B). We also observed a
tendency for an increase in the coverage with activated microglia
(Appendix Fig S4C and D) as well as occasional colocalization of
CD8-positive microglia and pS129-positive aggregates (Appendix Fig
S4E). However, variation between samples is high and the effect is
not significant.
Seeded a-synuclein aggregates have detrimental effects on
dendrites and spines
Advantageous to other mouse models, the seeding model does not
require a disease-related transgene to induce a pathologic pheno-
type. In this way, we wanted to investigate structural alterations
that might be the consequence of dose- and time-controlled molecu-
lar templating of a-syn aggregates. Five months after the injection of
PFFs or PBS (control) into the dorsal striatum, brain slices were
stained for pS129-positive a-syn aggregates, which were most abun-
dant in layer IV and upper layer V of the cortex, including pyramidal
eGFP-expressing neurons (Appendix Fig S3A). In order to study
whether structural changes might be solely attributed to a local
effect of intracellular aggregates on neighboring dendrites or due to
a more global disturbance in the synaptic network, we imaged
apical dendrites located in two different layers (Fig 4A). Dendrites
imaged in layer IV or V were spatially close to cells bearing an intra-
neuronal a-syn accumulation, while tuft dendrites of layer I were
distal to these cells (Fig 4B).
Indeed, we found alterations in spine density irrespective of the
cortical location of the dendrites. In both layer IV/V (t(11) = 3.628;
P = 0.004) and layer I (t(11) = 3.838; P = 0.0028), spine density was
found to be lowered in brains which had been injected with PFFs
and contained a-syn aggregates (Fig 4C).
We next investigated how vulnerable the morphological spine
types are in response to seeded a-syn. In the layer IV/V dendrites,
all types were lost to the same extent, leaving the fractions of mush-
room, stubby, and thin spines comparable in controls and seeded
animals (Appendix Fig S5B and Fig 4C). Contrarily, in apical tuft
dendrites (layer I), thin spines proved to be more and stubby spines
less vulnerable to seeded a-syn. The fraction of thin spines was
therefore decreased (t(11) = 2.350; P = 0.0385), while the fraction
of stubby spines was increased (t(11) = 2.599; P = 0.0247)
(Appendix Fig S5A and Fig 4C). This phenotype was already
observed in our ex vivo spine data of young transgenic h-a-syn mice
(see Fig 2) and could be reproduced here. On the presynaptic side,
no overt change in the density of excitatory boutons could be
detected in both the transgenic and the seeding mouse model
(Appendix Fig S6I–L).
The irregular form of the tuft dendritic shafts in PFF-seeded
brains was an additional observation. In controls, injected only with
PBS, the diameter of dendritic shafts was found to be relatively
uniform. In contrast, apical tuft dendrites of PFF-seeded mice
showed an irregular appearance of the dendritic shaft. Over the
length of the dendrites, large swellings could be observed as well as
segments with an extremely narrow diameter (Fig 4D). In a histo-
gram plotting the frequency of diameter values, dendritic shaft
diameters follow a normal distribution (R2 = 0.9263) for the control
animals. For the seeded mice, the variety of values is broader and
the values are best described with two distributions: one at very low
dendritic diameter (R2 = 0.9250) and one comparable to the control
distribution (R2 = 0.9664), with the exception of the presence of
abnormally high values (Fig 4E). As a consequence of the high vari-
ation, the mean standard deviation of the dendritic shaft diameter
was found to be significantly increased (t(11) = 3.054; P = 0.011) in
mice that were seeded with a-syn PFFs (Fig 4F). Note that this
phenotype was only observed in our seeding, but not in the trans-
genic model.
With our approach, we could show that the introduction of
a-synuclein seeds and the consecutive accumulation in the cerebral
◀ Figure 3. Injection of PFFs into the dorsal striatum triggers cortical a-synuclein aggregation.A–C The quality of the injection material was verified using ThT fluorescence assay (A), sucrose-gradient fractionation (B), and electron microscopy (C).
Scale bar: 0.2 lm.
D Injection site, 0.2 mm anterior of the bregma (star) and imaging area (box) as depicted in (E).
E–I Representative images of the cortical layers I–VI in the somatosensory cortex of mice at different time points postinjection. Controls were injected with sterile PBS.
Neurons in the layers IV and V of the somatosensory cortex contain aggregates of a-synuclein phosphorylated at S129 (F), which are ubiquitin-positive (G) as well
as thioflavin S-positive (H, I). Image stacks (E–I) are depicted as maximum intensity projections. Scale bars: 50 lm (E), 10 lm (F, G), 20 lm (H), 5 lm (I).
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cortex triggers structural changes both at the level of the dendritic
spine and the dendritic shaft.
Discussion
This study presents converging evidence from two distinct
approaches for the adverse effects of a-syn accumulation for the
density and structural plasticity of dendritic spines in the cerebral
cortex. Dendritic spines are excitatory postsynapses, and their loss
has been described repeatedly as a structural correlate for cognitive
impairment and dementia (Terry et al, 1991; Dickson et al, 1995;
Bellucci et al, 2012; Picconi et al, 2012). Moreover, the effects of
mutated and accumulated a-syn have been studied in several brain
regions. Striatal spine loss has been reported in various animal
models of PD and in PD and DLB patients (McNeill et al, 1988;
Zaja-Milatovic et al, 2006). In a mouse model overexpressing the
human A53T a-syn mutation, spine loss has been observed in the
A C
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Figure 4. The presence of accumulated a-synuclein induced by seeding 5 months prior to analysis causes spine loss and malformation in layer V apical
dendrites.
A a-Synuclein aggregates occur as intrasomal (arrowheads) and neuritic (arrows) accumulations and are present predominantly in upper layer V and layer IV of the
cortex. In layer I, pS129-positive structures are much less dense. Lines exemplarily mark dendrites used for analysis.
B Spine analysis was performed on apical dendrites located in the cortical layers IV/V and I.
C In layer I, spine density is reduced relative to PBS-injected controls (**P = 0.0028), with the fraction of stubby spines being increased (*P = 0.0247) and the fraction of
thin spines being decreased (*P = 0.0385). In layer IV/V, spine density is reduced as well (**P = 0.004), without a significant effect on spine morphology.
D In apical tuft dendrites of PFF-injected mice, dendrites display dystrophic swellings and parts of very small diameter; white lines: measurement positions.
E Histograms of the dendritic shaft diameter.
F Variation in the diameter of single dendrites in seeded mice compared to controls (*P = 0.011).
Data information: n = 6 (control), n = 7 (PFF) animals, mean with s.e.m.; Student’s t-test: *P < 0.05, **P < 0.01. Scale bars: 20 lm (A), 2 lm (B, D).
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striatum and in the hippocampus (Finkelstein et al, 2016). Some
authors report that D2R striatopallidal neurons in reserpine and
6-OHDA-treated mice selectively lose spines (Day et al, 2006), while
others found spine loss on both direct and indirect pathway neurons
in 6-OHDA- or MPTP-treated models (Sua´rez et al, 2014). In
contrast, another study failed to detect striatal spine loss in A53T
mice, despite a decrease in the number of SNpc neurons (Oaks et al,
2013). a-syn was also demonstrated to have negative impact on
newly generated neurons of the hippocampus (Winner et al, 2012)
and the olfactory bulb (Neuner et al, 2014), particularly on their
dendrite outgrowth and spine development.
In our current study, we aimed to extend this knowledge with a
chronic examination of spines in the cortex. As the chronic effects
of a-syn on cortical spine plasticity remain incompletely understood,
we used two different mouse models which exhibit a-syn accumula-
tion in the cortex. In our transgenic model, wild-type human a-syn
was expressed under the PDGF promoter, leading to neocortical
accumulation of mostly soluble protein located as inclusions in
neuronal cell bodies as well as synaptic terminals (Masliah, 2000;
Rockenstein et al, 2002; Amschl et al, 2013). Our seeding model
was based on the striatal injection of preformed wild-type mouse a-
syn fibrils and caused a slowly progressing phenotype of phosphory-
lated a-syn-positive neuronal inclusions, which first developed in
the deeper layers of the neocortex and condensed over time to
mature into fibrillary Lewy-like inclusions.
Our study also provides in vivo evidence that accumulation of
wild-type a-syn interferes with cortical spine plasticity and spine
density which declined in young adult mice starting from about
3 months of age and stabilized at a reduced overall density in older
mice (30%). This spine loss occurs well before behavioral impair-
ments become apparent in these mice (Masliah, 2000; Amschl et al,
2013) and may be the result of a presymptomatic change in pre- and
postsynaptic function.
While numerous studies have made great effort to unravel the
molecular mechanism behind a-syn toxicity, it remains to be clari-
fied whether a toxic gain-of-function or a loss-of-function or both is
responsible for synapse and cell loss. Among the toxic gain-of func-
tion effects of a-syn are the impairment of lysosomal and proteaso-
mal protein degradation, induction of endoplasmic reticulum (ER)
stress, Golgi fragmentation, and active formation of pores on cellu-
lar membranes (reviewed by Cookson & van der Brug, 2008). For
instance, it was shown that the acute application of a-synuclein
oligomers onto autaptic hippocampal cultures as well as onto
hippocampal slices significantly enhances basal NMDA receptor
activation and the amplitude of AMPA-receptor-mediated synaptic
currents (Hu¨ls et al, 2011; Diogenes et al, 2012). This augmented
excitatory transmission could be explained by (i) a-syn oligomer-
mediated pore formation in the postsynaptic membrane
(Volles et al, 2001; Furukawa et al, 2006; Schmidt et al, 2012),
(ii) enhancement of voltage-operated Ca2+ channel activity
(Hettiarachchi et al, 2009), or (iii) inefficient membrane repolariza-
tion (Shrivastava et al, 2015), all causing increased calcium influx
which in turn results in AMPA-receptor recruitment to the dendritic
spine membrane (Byth, 2014). The resulting postsynapse is
saturated with receptors and therefore unable to recruit extra AMPA
receptors upon theta-burst stimulation which causes a long-term
potentiation (LTP) decline and overall excitotoxicity (Yuste &
Bonhoeffer, 2001; Diogenes et al, 2012). On the long term—as we
analyzed the structural impact of transgenic and seeded a-synuclein
during and after several months—this proposed mechanism based
on a slightly but chronically enhanced calcium influx may disturb
the tightly controlled, calcium-dependent machinery of synaptic
plasticity. Likewise, a primary presynaptic pathology might alter
synaptic vesicle release which as a long-term consequence may alter
dendritic spine plasticity. Excessive a-synuclein has been shown to
inhibit neurotransmitter release via specifically reducing the size of
the synaptic vesicle recycling pool (Nemani et al, 2010) as well as
to regulate SNARE-driven membrane fusion (Garcia-Reitbock et al,
2010; Burre et al, 2015). A study in DLB brain tissue showed
massive deposits of diffuse aggregates in the cortical and subcortical
gray matter, which were located at synaptic terminals and were
linked to dendritic spine loss. This suggests that the subcellular
presynaptic location of a-syn is important for its neurodegenerative
effect (Kramer & Schulz-Schaeffer, 2007) and although our models
show no overt presynaptic loss, an alteration in function seems
likely. The functional roles of a-synuclein, in conjunction with regu-
lating actin dynamics and chaperoning the polymerization of micro-
tubule-associated proteins (Sousa et al, 2009), would certainly
impair spine stability and dendritic plasticity (Tsaneva-Atanasova
et al, 2009).
The a-syn loss-of-function hypothesis comprises that with
progressing aggregation, endogenous a-syn becomes sequestered
into inclusions; be they oligomers, protofibrils, or mature LBs and
LNs, leaving less functional protein to perform normal cellular func-
tions (reviewed by Benskey et al, 2016). Particularly the changes
seen after seeding with PFFs are supportive of this hypothesis. As
previously shown and confirmed in this study through seeding of
fluorescently tagged a-syn fibrils, the aggregates formed are chiefly
composed of endogenous a-syn, with very little of the initial PFF
seed being part of the developed inclusions (Luk et al, 2009). The
concept of sequestration is further reinforced by the complete
absence of inclusions and toxicity in a-syn null mice seeded with
PFFs (Volpicelli-Daley et al, 2011; Luk et al, 2012a). To complicate
things even further, recent evidence suggests that microglial activity
can contribute to both detrimental and protective mechanisms in
neurodegenerative diseases (Morris et al, 2013; Miyamoto et al,
2016; Tang & Le, 2016). In our model, the infusion of PFFs did not
cause overt and chronic microglial activation at the observed time
point, but additional experiments might be necessary to gain a
broader picture about the glial involvement in a-syn-affected
synapse dynamics.
From our imaging data, we cannot pin down which of these
described mechanisms exactly are involved in the loss of spines,
which emphasizes the need for further studies for clarification.
Furthermore, as our in vivo data suggest, the mechanism underlying
synapse loss and the shift in morphology may not even be uniform
throughout the course of disease. Spine dynamics were found to be
changed remarkably depending on the age of the animal upon
observation. The decrease in gained spines observed in 3-month-old
animals caused a progressive spine loss and is morphologically
reflected in the diminished fraction of thin spines, which are known
to correspond to non-synaptic transient precursors of the larger
stabilized spines (Holtmaat et al, 2005; Arellano et al, 2007).
Contrarily, in the two older groups (6 and 12 months), further spine
loss was restrained by an elevation of the daily turnover ratios. This
was in turn reflected by an increase in the fraction of thin spines.
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Thus, we propose that the observed spine remodeling in these
animals represents a compensatory mechanism for the loss of abso-
lute spine number, thereby strengthening the remaining synaptic
contacts.
In both our seeding and transgenic model, proteinaceous aggre-
gates are present in the neocortex, albeit in two histopathological
variances: while the PDGF promoter in the transgenic model drives
a more or less uniform accumulation of non-fibrillary (Masliah,
2000) a-syn in cortical neurons and synapses, seeding of PFFs leads
to the formation and maturation of fibrillary Lewy-like structures in
neurons connected to the dorsal striatum. Our results from our
in vivo study in young transgenic mice are in line with the dendritic
spine phenotype which can be induced through inoculation with
PFFs. Dendritic spine loss in layer V pyramidal neurons as well as a
redistribution of spine morphologies toward less thin spines can be
observed 5 months after inoculation with PFFs. The observed spine
loss was independent of whether the respective dendrite was
spatially close to the cortical layer V, in which neuronal a-syn
inclusions were most pronounced. Interestingly, dystrophic defor-
mation of apical tuft dendrites was present in PFF-seeded brains.
Dendritic varicosities have been described in other progressive
neurodegenerative diseases and have been linked to dendritic spine
loss in scrapie-injected rodents (Fuhrmann et al, 2007) and an
Alzheimer’s disease model (Bittner et al, 2010). The presence of
axonal varicosities caused by a-synuclein seeding has been reported
(Rockenstein et al, 2005); furthermore, it has been shown that
inclusions mature and condense over time and that aggregate bear-
ing neurons selectively degenerate (Osterberg et al, 2015). There-
fore, it seems likely that the degeneration of the respective cell body
and the accompanying transport deficits are the cause for
dystrophies and contribute to spine loss in our PFF-seeded brains.
For answering scientific questions, animal models in principle
comprise advantages as well as drawbacks (Bezard et al, 2013).
For example, all available genetic mouse models of synucle-
inopathies are able to model only a subset of symptoms known in
the human disease cases. Promoter-driven protein expression is
A
CB
Figure 5. Cortical a-synuclein accumulation and long-term in vivo imaging of PDGF-h-a-syn × GFP-M mice.
A Immunostaining with 15G7 antibody shows cortical layer V overexpression of a-synuclein (magenta) including accumulation in cell bodies (arrows).
B Experimental timeline: 4 weeks after window implantation (white arrowhead), imaging was performed over 6 weeks, once every 7 days (gray arrowheads) and finally
followed by perfusion and tissue fixation directly after the last imaging session (black arrowhead).
C Overview and detailed projections of eGFP-labeled layer V apical dendrites in the somatosensory cortex, imaged through a chronic cranial window.
Data information: Scale bars: 20 lm (A), 50 lm (C), 5 lm (C, inset).
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limited to a cell population in which the promoter is active and is
even complicated through the fact that background strain might
affect the expression pattern (Chesselet et al, 2008). Apart from
that, a-synuclein pathology induced by seeding of PFFs can be
induced in wild-type animals (Luk et al, 2012a) in a dose- and
region-specific manner. Here, however, the unphysiologically large
protein amount used for “planting the seed” should be considered.
One strong point of our combined approach was to apply and
compare both models, in order to best break down the actual
structural impact of a-syn accumulation on cortical neurons.
Collectively, our results support the idea that a-syn homeostasis is
constantly balanced on a knife-edge and that perturbations that
change its expression produces neurotoxicity with a common
mechanism in which the critical events are protein misfolding,
aggregate deposition, aggregate propagation, and synaptic dysfunc-
tion (Jucker & Walker, 2011; Guo & Lee, 2014; Luna & Luk, 2015).
Our data provide evidence for the harmful structural consequences
of excessive wild-type a-synuclein on cortical dendrites throughout
different pathological stages and may pave the way toward new
therapeutic strategies for PD and DLB that focus on the mainte-
nance of synaptic function.
Materials and Methods
Animals
PDGF-h-a-syn animals were obtained from QPS Austria Neurophar-
macology (Grambach, Austria) and bred on a C57Bl/6 background.
These transgenic mice overexpress human a-synuclein (h-a-syn)
under the regulatory control of the human platelet-derived growth
factor-b (PDGF-b) promoter (Masliah, 2000). Expression is strongest
in the neocortex, hippocampus, olfactory bulb, and limbic system,
leading to intraneuronal and synaptic a-syn accumulation as early
as 3 months of age (Fig 5A and Appendix Fig S6A–D) as well as
progressive motor deficits (Masliah, 2000; Amschl et al, 2013).
Furthermore, C57Bl/6 wild type, Thy1-eGFP transgenic mice (GFP-
M) (Jackson Laboratory, Bar Harbor, ME, USA), and a-syn knock-
out (SNCA KO) mice (Abeliovich et al, 2000) were used. For in vivo
imaging, the heterozygous PDGF-h-a-syn × GFP-M (termed h-a-syn
in this paper) line was created by interbreeding and the experiment
involved three age cohorts of both male and female mice, in which
mice were 3, 6 or 12 months old at the first imaging time point. All
animals were housed in groups under pathogen-free conditions and
bred in the animal housing facility at the Center for Neuropatho-
logy and Prion Research of the Ludwig Maximilians University of
Munich, with food and water provided ad libitum (21  2°C, at
12/12-h light/dark cycle). After cranial window implantation, mice
were housed separately. All experiments were approved by the
Bavarian government (Az. 55.2-1-54-2532-163-13) and performed
according to the animal protection law.
Injection material and stereotactic injection
Recombinant wild-type mouse a-synuclein was expressed in BL21
(DE3) E. coli using a pRK172 plasmid (kind gift from Kelvin Luk
and Virginia Lee, University of Pennsylvania, USA) as previously
described (Nuscher et al, 2004; Kostka et al, 2008). Briefly,
Escherichia coli BL21(DE3) (Invitrogen, MA, USA) were trans-
formed with the plasmid, and expression was induced with
isopropyl b-D-1-thiogalactopyranoside (IPTG, Peqlab, Erlangen,
Germany). Cells were lysed by boiling after heat-inactivation of
proteases. After centrifugation, the supernatant was filtered
through Filtropur S 0.2 filters (Sarstedt, Nu¨mbrecht, Germany),
loaded on a HiTrap Q HP anion-exchange column (5 ml, GE
Healthcare, Munich, Germany) and eluted with a linear 25 mM to
500 mM NaCl gradient. Synuclein containing fractions were
concentrated using VivaSpin 2 columns (Sartorius, Go¨ttingen,
Germany). Protein concentration was assessed to 5 mg/ml in
50 mM Tris–HCl, pH = 7.0. After freezing in liquid nitrogen, the
protein was stored at 80°C. Appendix Fig S2A shows blots from
the monomer preparation. Preformed fibrils (PFFs) were assem-
bled from purified a-synuclein monomer (5 mg/ml) by incubation
at 37°C with constant agitation (1,400 rpm) in an orbital mixer
(Eppendorf, Hamburg, Germany) for 96 h and stored at 80°C
(Conway et al, 2000; Deeg et al, 2015). For fluorescent labeling,
purified a-synuclein monomer (3.75 mg/ml, containing 100 mM
NaHCO3) was incubated with 0.34 mg/ml Alexa Fluor
 488 NHS
Ester (Life Technologies, Darmstadt, Germany) for 18 h at 4°C.
The remaining free fluorophore was removed from the solution
using PD-10 columns (GE Healthcare, PA, USA) according to the
manufacturer’s recommendations prior to fibril assembly as
described above. Directly before injection, an aliquot of PFFs was
sonicated four times with a handheld probe (SonoPuls Mini 20,
MS1.5, Bandelin, Berlin, Germany) according to the following
protocol: amplitude 30%; time 15 s (pulse on 3 s, pulse off 6 s).
Two-month-old mice (male or female) were anesthetized with
ketamine/xylazine (0.13/0.01 mg/g body weight; WDT/Bayer
Health Care, Garbsen/Leverkusen, Germany) and stereotactically
injected with 5 ll (25 lg) of PFFs into the dorsal striatum (coordi-
nates relative to the bregma: +0.2 mm anterior, +2.0 mm from
midline, +2.6 mm beneath the dura) of the right hemisphere using
a 5-ll Hamilton syringe. Injections were performed at 400 nl/min
with the needle in place after injection for at least 5 min. Control
animals received sterile PBS or 5 ll of 5 mg/ml monomeric
a-synuclein. Animals were monitored regularly after the surgery
and sacrificed at different predetermined time points (30 days,
60 days, 90 days, 5 months, and 9 months after injections) for
perfusion and tissue fixation with 4% paraformaldehyde.
Thioflavin T binding and sucrose gradient
For in vitro measurement of thioflavin T (ThT) binding, 10 lM ThT
was added to 100 lg/ml monomeric a-synuclein or PFFs and incu-
bated at 30°C for 10 min. Fluorescence signal was excited at 420–
460 nm and emission detected at 460–500 nm with a spectrofluorometer
(FluoStar Optima, BMG Lab Tech, Jena, Germany). Continuous
sucrose-gradient assay was performed as described previously
(Friedlander et al, 2002; Wagner et al, 2013). Briefly, six layers of
solutions with decreasing sucrose concentration (50 mM Tris pH
7.5, 0.1% NP-40, 10–60% D(+)-sucrose, respectively) were filled
into a 4 ml 11 × 60 mm polyallomer tube (Beckman Coulter, CA,
USA). Finally, 200 ll of 5 lM protein in 1× TBS (pH 7.5) containing
0.1% NP-40 was loaded on the top of the gradient. Ultracentrifuga-
tion with 100,000 g at 4°C for 1 h was performed using a Sw60Ti
rotor (Beckman Coulter, USA). Resulting continuous gradients were
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fractionated in volumes of 200 ll. 20 ll per fraction was analyzed
by denaturing Western blot using a monoclonal antibody against
mouse-a-synuclein (New England Biolabs, Frankfurt, Germany).
Electron microscopy
a-Synuclein fibrils diluted to 5 lM in H2O were adsorbed onto a
Formvar-coated, carbon-stabilized copper grid. The grid was then
rinsed briefly with H2O and stained with uranyl acetate and lead
citrate. Digital images were captured at different magnifications on a
Jeol JEM-1011 TEM (JEOL Inc., MA, USA) equipped with an 11
megapixel Orius CCD digital camera (Gatan Inc. CA, USA).
Cranial window
A cranial window was implanted over the right cortical hemisphere
as previously reported (Fuhrmann et al, 2007). In short, the mice
were given an intraperitoneal injection of ketamine/xylazine to
reach surgical anesthesia. Additionally, dexamethasone (0.01 mg/g
body weight; CP Pharma, Burgdorf, Germany) was intraperitoneally
administered immediately before surgery (Holtmaat et al, 2009). A
circular piece of the skull (4 mm in diameter) over the right hemi-
sphere (centered over the parietal bone, approx. 5.5 mm caudal
from the bregma and 5.5 mm lateral from midline) was removed
using a dental drill (Schick-Technikmaster C1; Pluradent; Offen-
bach, Germany). The craniotomy was closed immediately with a
round coverslip (4 mm in diameter), held with dental acrylic. A
small z-shaped titan bar was glued next to the coverslip to allow
repositioning of the mouse during subsequent imaging sessions.
After surgery, mice received subcutaneous analgesic treatment with
carprofen (5 mg/kg body weight; Rimadyl; Pfizer, NY, USA) and
antibiotic treatment with cefotaxime (0.06 mg/kg body weight;
Sanofi-Aventis, Frankfurt, Germany).
Long-term in vivo imaging
Imaging started 4 weeks after the cranial window preparation to
allow the animals to recover from surgery. After 6 weekly 2-photon
in vivo imaging sessions, mice were sacrificed and their brains were
fixed for further analyses (Fig 5B). Two-photon imaging was
performed on a LSM 7 MP (Zeiss, Jena, Germany) equipped with
GaAsP detectors and a 20× water-immersion objective (W Plan-
Apochromat 20×/1.0 DIC, 1.0 NA, Zeiss, Jena, Germany). eGFP was
excited at 880 nm by a Ti:Sa laser (MaiTai DeepSee, Spectra-
Physics, Darmstadt, Germany), and emission was collected from
440 to 500 nm. Image stacks of 425 × 425 × 249 lm3 were acquired
using the “z-stack” mode of the microscope control software
(ZEN 2012/ZEN 2010 64-bit) with a lateral resolution of 0.83 and
3 lm separation distance between consecutive images. Mice were
anesthetized with isoflurane (CP Pharma, Burgdorf, Germany) for
imaging and fixed to a custom-made head holder using the attached
metal bar. In subsequent imaging sessions, previously imaged
volumes were identified by eye using the unique blood vessel
pattern and fine adjusted by the position of previously imaged
dendrites. This method enabled precise alignment of the same imag-
ing volume over a period of 6 weeks (Fig 5C; Helmchen & Denk,
2005). In order to maintain stable fluorescence emission levels, the
laser power was adjusted relative to imaging depth.
Image processing and analysis of in vivo and ex vivo data
For image analysis, only microscope image data with sufficient
eGFP expression and good signal-to-noise ratio over time were
included and the experimenter was blinded to the genotype of the
mice by assigning a random number to each animal. From each
mouse (male or female, n = 4–5 in vivo, n = 6–7 seeding experi-
ment, without randomization), 9–10 dendrites from at least three
different positions underneath the cranial window or in slices were
analyzed. The length of individual dendrites was measured in ZEN
2012 (Zeiss). Spines identified along the dendrite were marked as
gained, lost, or stable. The mean density of dendritic spines was
estimated for each time point and expressed over 1 lm of dendrite
length. The stability of spines was calculated based on the amount
of spines that remained unaltered for at least two subsequent imag-
ing sessions. The spine turnover rate (TOR) was assessed based on
gain and loss of spines over each day of imaging, calculated as
follows: TOR = (Ngained + Nlost)/(2 × Npresent)/It, where Ngained,
Nlost, and Npresent represent the number of gained, lost, or total
spines at time points of interest, respectively, while It is the number
of days between consecutive imaging sessions. Ex vivo image anal-
ysis measurements were performed manually from maximal projec-
tion images of deconvoluted (AutoQuantX3, Media Cybernetics)
confocal stacks. All spines along the dendrite were marked and
categorized into three morphologically different classes, according
to established criteria (Jung et al, 2011). For analysis of the
dendritic diameter, length measurements were taken every 40
pixels along the dendritic shaft (control: 756 measurements,
n = 6, PFF-seeded: 840 measurements, n = 7) using ImageJ. To
quantify the density of glutamatergic presynaptic boutons VGLUT1-
positive Imaris 7.7.2 software was applied to detect VGLUT1-
positive puncta. In detail, the spots detection algorithm was applied
using an estimated diameter of 0.5 lm in xy and an 1.5 lm in z.
Background subtraction was enabled, and region-growing type was
set to local contrast with a manual threshold of 30 defined for all
datasets. Only spots with a xy diameter greater than 0.4 lm were
counted as boutons. The data were compiled in MATLAB using
ImarisXT interface.
Statistical analysis
The sample size of animals and imaged dendrites per animal
were chosen according to our previous experience in long-term
imaging (Neuner et al, 2014; Filser et al, 2015). Graphs were
created, and statistics were calculated in Prism v 5.04 (GraphPad
Software, San Diego, CA, USA). For in vivo time series data, two-
way ANOVA followed by the Bonferroni’s post hoc test was used
to compare the variance of spine parameters assessed over time
in control and h-a-syn animals. For assessment of inter-group dif-
ferences at single time points, Student’s t-test (unpaired, two-
sided) was applied. Normal distribution was assumed according
to the central limit theorem, as spine densities were calculated as
the means of means for every mouse. For t-tests, the variance
between groups was tested (F-test) and not found to be signifi-
cantly different. Data are expressed as mean  SEM unless other-
wise indicated, with P < 0.05 defining differences as statistically
significant (*P < 0.05; **P < 0.01; ***P < 0.001; for post hoc test:
#P < 0.05; ##P < 0.01).
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Immunohistochemistry and confocal microscopy
Animals in deep ketamine/xylazine anesthesia were killed by tran-
scardiac perfusion with 1× phosphate-buffered saline (PBS)
followed by 4% paraformaldehyde (w/v). The brains were postfixed
in PBS containing 4% paraformaldehyde overnight before cutting
60-lm-thick coronal sections on a vibratome (VT 1000S from Leica,
Wetzlar, Germany). Immunofluorescence staining was performed
on free-floating sections. Primary antibody incubation (overnight or
48 h (anti-VGLUT1), 4°C) was followed by 2 h of secondary anti-
body incubation at room temperature. Appendix Table S1 lists the
antibodies used in this study. For unambiguous analysis of GFP-
labeled neurons in eGFP-M mice, slices for spine analysis were
re-stained with anti-GFP Alexa Fluor 488 antibody (Invitrogen, Life
Technologies GmbH). Sections for the study of neuronal a-syn
accumulation were incubated with a fluorescent Nissl stain (Neuro-
traceTM 435/455, Thermo Fisher Scientific, USA). For mounting on
glass coverslips, VECTASHIELD Mounting Medium (Vector Labo-
ratories) was used. Laser wavelengths used for excitation and
collection range of emitted signals were as follows: Alexa Fluor
488/eGFP—488 nm/500–550 nm; Alexa Fluor 594—561 nm/585–743;
Alexa Fluor 647—633 nm/long-pass 650 nm; Nissl—750 nm/
435–485 nm. Analysis of dendritic spines was limited to cortical
apical dendrites from layer V neurons, cropped, and imaged at high
resolution. For imaging of presynaptic boutons, three-dimensional
16-bit data stacks of 1,024 × 1,024 × 26 pixels were acquired from
four different positions in the somatosensory cortex at a lateral reso-
lution of 0.1 lm/pixel and an axial resolution of 0.4 lm/pixel.
Appendix Fig S6E–H illustrates the automatic bouton detection
applying the algorithm.
Expanded View for this article is available online.
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